Circulating galanin and IL-6 concentrations in gestational diabetes mellitus

References

• The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2002;25:5–20
   Google Scholar
• Richardson AC, Carpenter MW. Inflammatory mediators in gestational diabetes mellitus. Obstet Gynecol Clin North Am 2007;34:213–24, viii
   PubMed Web of Science ®Google Scholar
• Tatemoto K, Rökaeus A, Jornvall H, et al. Galanin – a novel biologically active peptide from porcine intestine. FEBS Lett 1983;164:124−8
   PubMed Web of Science ®Google Scholar
• Fang PH, Yu M, Ma YP, et al. Central nervous system regulation of food intake and energy expenditure: role of galanin-mediated feeding behavior. Neurosci Bull 2011;27:407–12
   PubMed Web of Science ®Google Scholar
• Izdebska K, Ciosek J. Galanin influences on vasopressin and oxytocin release: in vitro studies. Neuropeptides 2010;44:341–8
   PubMed Web of Science ®Google Scholar
• Jaroslaw R, Magdalena C, Czeslaw W, Piotr R. Effects of porcine galanin, galanin (1–15) NH2 and its new analogues on glucose-induced insulin secretion. Pol J Pharmacol 2002;54:133–41
   PubMedGoogle Scholar
• Lang R, Kofler B. The galanin peptide family in inflammation. Neuropeptides 2011;45:1–8
   PubMed Web of Science ®Google Scholar
• Mitsukawa K, Lu X, Bartfai T. Galanin, galanin receptors and drug targets. Cell Mol Life Sci 2008;65:1796–805
   PubMed Web of Science ®Google Scholar
• Liang Y, Sheng S, Fang P, et al. Exercise-induced galanin release facilitated GLUT4 translocation in adipocytes of type 2 diabetic rats. Pharmacol Biochem Behav 2012;100:554–9
   PubMed Web of Science ®Google Scholar
• Jiang L, Shi M, Guo L, et al. Effect of M35, a neuropeptide galanin antagonist on glucose uptake translated by glucose transporter 4 in trained rat skeletal muscle. Neurosci Lett 2009;467:178–81
   PubMed Web of Science ®Google Scholar
• He B, Shi M, Zhang L, et al. Beneficial effect of galanin on insulin sensitivity in muscle of type 2 diabetic rats. Physiol Behav 2011;103:284–9
   PubMed Web of Science ®Google Scholar
• Matarese G, La Cava A, Sanna V, et al. Balancing susceptibility to infection and autoimmunity: a role for leptin?. Trends Immunol 2002;23:182–7
   PubMed Web of Science ®Google Scholar
• ACOG Practice Bulletin No. 137. Gestational diabetes mellitus. Obstet Gynecol 2013;122:406–16
   PubMedGoogle Scholar
• Radikova Z. Assessment of insulin sensitivity/resistance in epidemiological studies. Endocr Regul 2003;37:189–94
   PubMedGoogle Scholar
• Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19
   PubMed Web of Science ®Google Scholar
• Fang P, Yu M, Shi M, et al. Galanin peptide family as a modulating target for contribution to metabolic syndrome. Gen Comp Endocrinol 2012;179:115–20
   PubMed Web of Science ®Google Scholar
• Adeghate E, Ponery AS. Large reduction in the number of galaninimmunoreactive cells in pancreatic islets of diabetic rats. J Neuroendocrinol 2001;13:706–10
   PubMed Web of Science ®Google Scholar
• Ahren B, Pacini G, Wynick D, et al. Loss-of-function mutation of the galanin gene is associated with perturbed islet function in mice. Endocrinol 2004;145:3190–6
   PubMed Web of Science ®Google Scholar
• Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes 1994;43:613–21
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. Mechanisms of TNF-alpha-induced insulin resistance. Exp Clin Endocrinol Diabetes 1999;107:119–25
   PubMed Web of Science ®Google Scholar
• Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002;51:3391–9
   PubMed Web of Science ®Google Scholar
• Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286–92
   PubMed Web of Science ®Google Scholar
• Ategbo JM, Grissa O, Yessoufou A, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. J Clin Endocrinol Metab 2006;91:4137–43
   PubMed Web of Science ®Google Scholar
• Morisset AS, Dub’e MC, Cot’e JA, et al. Circulating interleukin-6 concentrations during and after gestational diabetes mellitus. Acta Obstetric Gynecol Scand 2011;90:524–30
   PubMed Web of Science ®Google Scholar
• Wolf M, Sauk J, Shah A, et al. Inflammation and glucose intolerance: a prospective study of gestational diabetes mellitus. Diabetes Care 2004;27:21–7
   PubMed Web of Science ®Google Scholar
• Morisset AS, Huot C, Legare D, Tchernof A. Circulating IL-6 concentrations and abdominal adipocyte isoproterenol stimulated lipolysis in women. Obesity (Silver Spring) 2008;16:1487–92
   PubMed Web of Science ®Google Scholar
• Invitti C, Brunani A, Pasqualinotto L, et al. Plasma galanin concentrations in obese, normal weight and anorectic women. Int J Obes Relat Metab Disord 1995;19:347−9
   PubMed Web of Science ®Google Scholar
• Legakis IN, Mantzouridis T, Mountokalakis T. Positive correlation of galanin with glucose in healthy volunteers during an oral glucose tolerance test. Horm Metab Res 2007;39:53–5
   PubMed Web of Science ®Google Scholar
• Vendrell J, Broch M, Fernandez-Real JM, et al. Tumour necrosis factor receptors (TNFRs) in Type 2 diabetes. Analysis of soluble plasma fractions and genetic variations of TNFR2 gene in a case-control study. Diabet Med 2005;22:387–92
   PubMed Web of Science ®Google Scholar
• Narváez JA, Diaz Z, Aguirre JA, et al. Intracisternally injected galanin (1–15) modulates the cardiovascular responses of galanin-(1-28) and the 5-HT1A receptor agonist 8-OH-DPAT. Eur J Pharmacol 1994;257:257–65
   PubMed Web of Science ®Google Scholar
• Díaz-Cabiale Z, Narváez JA, Yanaihara N, et al. Galanin/alpha2-receptor interactions in central cardiovascular control. Neuropharmacology 2000;39:1377–85
   PubMed Web of Science ®Google Scholar
• Díaz-Cabiale Z, Parrado C, Vela C, et al. Role of galanin and galanin (1-15) on central cardiovascular control. Neuropeptides 2005;39:185–90
   PubMed Web of Science ®Google Scholar
• Abbott SB, Pilowsky PM. Galanin microinjection into rostral ventrolateral medulla of the rat is hypotensive and attenuates sympathetic chemoreflex. Am J Physiol Regul Integr Comp Physiol 2009;296:R1019–26
   PubMed Web of Science ®Google Scholar
• Alston EN, Parrish DC, Hasan W, et al. Cardiac ischemia – reperfusion regulates sympathetic neuropeptide expression through gp130-dependent and independent mechanisms. Neuropeptides 2011;45:33–42
   PubMed Web of Science ®Google Scholar
• Habecker BA, Gritman KR, Willison BD, Van Winkle DM. Myocardial infarction stimulates galanin expression in cardiac sympathetic neurons. Neuropeptides 2005;39:89–95
   PubMed Web of Science ®Google Scholar
• Xu X, Liu Z, Liu H, et al. The effects of galanin on neuropathic pain in streptozotocin-induced diabetic rats. Eur J Pharmacol 2012;680:1–3,28–33
   PubMed Web of Science ®Google Scholar